FIG.: Consecutive sections showing 2 different HFs. It is possible to observe in both HFs the dermal papila, hair matrix, outer and inner root sheath and hair shaft.

Our main focus is to produce hair-follicles for hair-loss treatment in clinics and transplantation into the human scalp.

With it’s patent filed high-tech 3D stem cell merger technology INVITROHAIR, a spin-off from an EUROPEAN CONTRACT RESEARCH ORGANISATION, performs its own development-equivalent to pharmaceutical and cosmetics companies - in the drug discovery and preclinical testing phase, to increase their efficiency and the success rate of compounds that pass the clinical trials, i.e. enhanced relevance. 

Here we focus on ALOPECIA diseases, the performance  of higly sophisticated tissue (hair)-engineering and Insilico computerial screening technologies .

Prior to the transplantation of bioengineered Hairfollicles we will provide to patients cell viability/proliferation assays, DERMAL PAPILLAE isolation, HAIR BULGE STEM CELL isolation, IPSC reprogramming, tissue engineering and cryogenic storage.

The approach requires intensive identification of pathogenic conditions and the precise identification of specific phenotypes.

We're following the P4 MEDICINE PRINCIPLES.

-This service is only offered to physicians after regulatory clearance- 


Figure 1: migration from the attached DP

Figure 2: Organoid merged. 92 days old

Figure 3: de novo human hairfollicle prototype fixed in 4% PFA. Based on our US- PCT